Skip to main content
. Author manuscript; available in PMC: 2022 Sep 6.
Published in final edited form as: Cell Rep. 2022 Aug 16;40(7):111203. doi: 10.1016/j.celrep.2022.111203

Figure 1. STK25 inhibits PKA activity.

Figure 1.

(A) Differential phosphoproteomic spectra of STK25+/+ and STK25−/− cardiomyocytes. Members of the PKA signaling pathway are highlighted.

(B) Ingenuity phosphoprotein pathway analysis. Orange indicates pathways upregulated in STK25−/− cardiomyocytes, while blue indicates upregulation in STK25+/+.

(C) PKA activity in response to 10 μM forskolin treatment for 30 min in STK25+/+ and STK25−/− cardiomyocytes. n = 3 for each condition.

(D) PKA activity in response to 10 μM forskolin treatment for 30 min in HEK293T cells overexpressing either empty vector, wild-type STK2,5 or kinase-dead K49R/T174A. n = 3 for each.

Bar graph data are represented as mean ± SD and analyzed in technical triplicates, *p < 0.05, **p < 0.01, ****p < 0.0001 using ANOVA and Tukey’s adjustment for multiple comparisons.